title: Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.
abstract: BACKGROUND
  There have been concerns about the cardiovascular safety of omalizumab.
  
  
  OBJECTIVE
  In this study, the clinical status of the omalizumab receiving severe asthma patients and the cytokine expressions patterns were investigated.
  
  
  METHODS
  In a pilot study described below we examined the levels of serum eosinophil cationic peptid (ECP), CD200, d-dimer, 25-hydroxyvitamin D (25(OH)D), CXCL8 and IL-1β in asthma patients treated with anti-IgE therapy, to explore their relationship with disease activity, and the impact of anti-IgE therapy impact on those levels. Exercise stress testing and blood samples were taken at all follow up visits from the time of first diagnosis and after 20 months of treatment during the disease remission.
  
  
  RESULTS
  Fractional exhaled nitric oxide concentrations and serum levels of sTRAIL, sCD200, D-dimer, ECP, total IgE, IL-1β and Hs-CRP were decreased while CXCL8, 25(OH)D were increased after starting the treatment of anti-IgE. Our first case of a patient, who had both protein C and S deficiency and hence a high risk for thromboembolism, documents for the first time the safety of omalizumab for asthmatic patients with concurrent risk factors contributing to arteriothrombotic events.
  
  
  CONCLUSIONS
  Omalizumab might be used carefully in patients with cardiovascular diseases.
authors.affiliation: Antalya Training and Research Hospital, Allergy and Clinical Immunology Unit, Antalya, Turkey.
authors.forename: Arzu Didem
authors.initials: AD
authors.lastname: Yalcin
authors.forename: Aykut
authors.initials: A
authors.lastname: Cilli
authors.forename: Atil
authors.initials: A
authors.lastname: Bisgin
authors.forename: Ludwig G
authors.initials: LG
authors.lastname: Strauss
authors.forename: Felix
authors.initials: F
authors.lastname: Herth
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000150:complications*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; C508606:CXCL8 protein, human; D005338:Fibrin Fibrinogen Degradation Products; D053583:Interleukin-1beta; D016209:Interleukin-8; C036309:fibrin fragment D; D014807:Vitamin D; D000069444:Omalizumab; C104450:25-hydroxyvitamin D; C042739:antigens, CD200